At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AUPH Aurinia Pharmaceuticals
Market Closed 03-13 16:00:00 EDT
13.95
-0.42
-2.92%
盘后13.95
+0.000.00%
17:08 EDT
High14.51Low13.87Vol1.00M
Open14.43D1 Closing14.37Amplitude4.45%
Mkt Cap1.85BTradable Cap1.79BTotal Shares132.97M
T/O14.06MT/O Rate0.78%Tradable Shares128.06M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

13D Filings -- Barrons.com
Dow Jones  ·  03-14 08:29
13D Filings -- Barrons.com
The Bull Case For Aurinia Pharmaceuticals (AUPH) Could Change Following Strong 2025 Results And Upbeat 2026 Outlook
Simply Wall St.  ·  03-09
The Bull Case For Aurinia Pharmaceuticals (AUPH) Could Change Following Strong 2025 Results And Upbeat 2026 Outlook
Angkor Resources Closes $4.8M Sale of Evesham Oil and Gas Assets
Reuters  ·  03-06
Angkor Resources Closes $4.8M Sale of Evesham Oil and Gas Assets
Aurinia Pharmaceuticals Earnings Call Highlights Growth And Risks
TIPRANKS  ·  03-06
Aurinia Pharmaceuticals Earnings Call Highlights Growth And Risks
Aurinia Pharmaceuticals Director Kevin Tang Reports Acquisition of Common Shares
Reuters  ·  03-04
Aurinia Pharmaceuticals Director Kevin Tang Reports Acquisition of Common Shares
Assessing Aurinia Pharmaceuticals (AUPH) Valuation After Recent Share Price Swings
Simply Wall St.  ·  03-04
Assessing Aurinia Pharmaceuticals (AUPH) Valuation After Recent Share Price Swings
Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH), MAIA Biotechnology, Inc. (MAIA) and CG Oncology, Inc. (CGON)
TIPRANKS  ·  03-02
Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH), MAIA Biotechnology, Inc. (MAIA) and CG Oncology, Inc. (CGON)
RBC Capital Remains a Hold on Aurinia Pharmaceuticals (AUPH)
TIPRANKS  ·  02-27
RBC Capital Remains a Hold on Aurinia Pharmaceuticals (AUPH)
Aurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets
Benzinga  ·  02-27
Aurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets
Stock Track | Aurinia Pharmaceuticals Plummets 5.13% Intraday as 2026 Revenue Guidance Misses Estimates
Stock Track  ·  02-27
Stock Track | Aurinia Pharmaceuticals Plummets 5.13% Intraday as 2026 Revenue Guidance Misses Estimates
UPDATE: Aurinia Pharmaceuticals Q4 Adj. EPS $0.26 Beats $0.22 Estimate
Benzinga  ·  02-26
UPDATE: Aurinia Pharmaceuticals Q4 Adj. EPS $0.26 Beats $0.22 Estimate
Stock Track | Aurinia Pharmaceuticals Soars 5.20% in Pre-market on Strong Q4 Earnings Beat and Robust Guidance
Stock Track  ·  02-26
Stock Track | Aurinia Pharmaceuticals Soars 5.20% in Pre-market on Strong Q4 Earnings Beat and Robust Guidance
Canada's Aurinia Pharma Q4 revenue jumps on LUPKYNIS demand
Reuters  ·  02-26
Canada's Aurinia Pharma Q4 revenue jumps on LUPKYNIS demand
GUIDANCE: (AUPH) Aurinia Pharmaceuticals Expects Full Year 2026 Revenue Range $315M - $325, vs. FactSet Est of $326.8M
MT Newswires Live  ·  02-26
GUIDANCE: (AUPH) Aurinia Pharmaceuticals Expects Full Year 2026 Revenue Range $315M - $325, vs. FactSet Est of $326.8M
Aurinia Pharmaceuticals reports Q4 EPS $1.53, consensus 22c
TIPRANKS  ·  02-26
Aurinia Pharmaceuticals reports Q4 EPS $1.53, consensus 22c
Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q4 EPS $1.53
MT Newswires Live  ·  02-26
Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q4 EPS $1.53
Aurinia Pharmaceuticals Q4 EPS $1.53, Sales $77.114M Beat $74.845M Estimate
Benzinga  ·  02-26
Aurinia Pharmaceuticals Q4 EPS $1.53, Sales $77.114M Beat $74.845M Estimate
BRIEF-Aurinia Pharmaceuticals Q4 Product Revenue USD 74.173 Million
Reuters  ·  02-26
BRIEF-Aurinia Pharmaceuticals Q4 Product Revenue USD 74.173 Million
Aurinia Pharmaceuticals Q4 Operating Income USD 33.239 Million
THOMSON REUTERS  ·  02-26
Aurinia Pharmaceuticals Q4 Operating Income USD 33.239 Million
Aurinia Pharmaceuticals Inc: Plan to Initiate a Clinical Study in an Additional Autoimmune Disease in H1 2026
THOMSON REUTERS  ·  02-26
Aurinia Pharmaceuticals Inc: Plan to Initiate a Clinical Study in an Additional Autoimmune Disease in H1 2026

Introduction

Company Name.
Aurinia Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
Issue price:
--